Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementRegence IR Opioid Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentRegencePolicy dru516

    Immediate-release (IR) Opioid Medication Products for Pain

    Customize your policy alerts

    Sign up for regence Policy dru516 alerts

    Get alerted when Policy dru516 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for immediate-release oral, nasal, and topical opioid medications used for pain, generally when opioid use exceeds 14 cumulative days in 30 days.

    Policy Summary
    PayerRegence
    PolicyImmediate-release (IR) Opioid Medication Products for Pain
    Policy CodePolicy dru516
    Change TypeNo material change
    Effective DateApril 1, 2026
    Last ReviewJan 22, 2026
    Next Review DateJanuary 1, 2027
    Key ActionFor non-cancer pain, document insufficient response to both non-opioid and non-pharmacological therapy unless medically contraindicated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    14 daysIR opioid therapy threshold
    1Grace fill within 60 days
    6 monthsNon-cancer pain review interval
    12 monthsCancer or sickle cell review interval
    50 MME/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Opioid-naive dose limit

    Coverage Criteria

    Continuation of therapy

    Immediate-release opioids may be considered medically necessary for continuation of therapy when all applicable criteria, including quantity limits and condition-specific review requirements, are met.

    Continuation therapy

    • Ongoing qualifying pain condition

      • Cancer-related pain or hospice: Document ongoing pain due to an active malignancy or eligibility for hospice care.Review at 12 months
      • Sickle cell disease: Document acute episodic pain associated with sickle cell disease.Review every 12 months
      • Non-cancer pain: Document ongoing chronic non-cancer pain and meet the applicable non-cancer pain criteria.Review at least every 6 months
    • Ongoing benefit and treatment-plan review: Current clinical documentation confirms that the comprehensive pain-management plan has been assessed and updated and that the patient is making progress toward the stated opioid-treatment goals.

      Continued coverage requires documentation of ongoing benefit and medical necessity.

    • Concurrent medication-assisted treatment, when applicable: If the immediate-release opioid is used concurrently with buprenorphine or buprenorphine/naloxone for opioid-dependence treatment, the prescriber provides documentation supporting the concurrent use.

    New starts / treatment-naive patients

    New-start treatment-naive patients may be covered when the therapy exceeds the policy threshold and one qualifying pathway is met.

    New-start eligibility

    • Extended immediate-release opioid therapy: Treatment is with any immediate-release opioid beyond 14 total days in 30 days.>14 days in 30 days

      Tramadol-containing products are excluded from this policy when prescribed up to the FDA-approved maximum dosage.

    • ONE qualifying pathway

      • A. Active cancer pain: The patient has an active diagnosis of chronic cancer pain due to an active malignancy.
      • B. Hospice eligibility: The patient is eligible for hospice care.

    Continued authorization

    Continued authorization requires condition-specific review and current documentation supporting ongoing medical necessity.

    Condition-specific continued authorization

    • ONE applicable pain condition

      • Cancer-related pain: Document ongoing pain due to an active malignancy or eligibility for hospice care.Review at 12 months

        If pain due to an active malignancy is not clearly documented, the non-cancer pain initial criteria must be met.

      • Acute episodic sickle cell pain: Document acute episodic pain associated with sickle cell disease.Review every 12 months
      • Non-cancer pain:

    Extended-duration immediate-release opioid therapy for acute pain, including post-operative pain, is not coverable. Short-acting immediate-release opioids may be appropriate for acute severe post-operative pain when used for the shortest necessary duration.

    Extended-release opioid products are addressed under a separate policy and are not governed by this immediate-release opioid policy.

    Ongoing opioid therapy without documentation of clinically meaningful improvement in pain is considered not medically necessary. Treatment should be reassessed against the patient’s documented pain-management and functional goals.

    Extended-duration immediate-release opioid therapy for acute or post-operative pain is not medically necessary and is not coverable.

    Coverage and Review Parameters

    Extended IR opioid therapy
    Extended-therapy thresholdMore than 14 cumulative days of opioid use in 30 days
    Coverage processImmediate-release opioid therapy beyond the threshold is subject to pre-authorization review
    Tramadol exceptionTramadol-containing products are not subject to this policy when prescribed up to the FDA-approved maximum dosage
    Grace fill
    Grace-fill limitUp to 1 grace fill within a 60-day period
    Additional therapyThe grace fill provides up to 7 additional days of therapy
    Purpose

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization for Extended IR Opioid Therapy

    Most contracts require prior authorization before coverage of immediate-release (IR) opioids. Treatment with any IR opioid beyond 14 total days in a 30-day period requires authorization for extended therapy.

    • Up to 14 days of therapy in 30 days may be available without pre-authorization review.
    • Requests beyond the 14-day threshold trigger an alert to seek pre-authorization.
    • Continuation of therapy is subject to all applicable policy criteria, including quantity limits.
    Prior Authorization

    New-Start Coverage Pathways

    For new starts or treatment-naïve patients requiring IR opioid therapy beyond 14 days in 30 days, coverage may be considered when one of the following pathways applies.

    • Active chronic cancer pain due to an active malignancy.
    • Eligible for hospice care.
    • Diagnosis of sickle cell disease, including episodic acute pain associated with SCD.

    Policy Background

    Immediate-release opioids are controlled substances used to manage moderate to severe pain. This policy directs appropriate use when pain is severe enough to require extended opioid therapy and alternative treatments are inadequate, while emphasizing the lowest effective dose for the shortest feasible duration. Pharmacologic treatment should be combined with non-pharmacological strategies and reassessed against objective pain and functional goals.

    Key Definitions

    Immediate-release opioid therapy for new starts
    DefinitionTreatment with any immediate-release opioid beyond 14 total days in 30 days
    Policy scopeThe policy applies to immediate-release opioids prescribed for more than 14 days of cumulative opioid use
    Tramadol exceptionTramadol-containing products are not subject to this policy when prescribed up to the FDA-approved maximum dosage
    Continuation of therapy (COT)
    DefinitionImmediate-release opioid therapy continued beyond the initial treatment period
    Coverage reviewContinuation of therapy may be considered medically necessary when the full policy criteria, including quantity limits, are met

    Conservative Treatment Requirements

    Conservative treatment requirements

    For non-cancer pain, maximize and document both medication-based and non-pharmacological treatment before extended-duration immediate-release opioid therapy, unless medically contraindicated.

    • Non-opioid therapy: Maximize non-opioid therapy and document that it was insufficient for pain control, unless medically contraindicated. Examples include acetaminophen, NSAIDs, antiepileptics, antidepressants, and selected topical agents.
    • Non-pharmacological therapy: Maximize non-pharmacological therapy and document that it was insufficient for pain control, unless medically contraindicated. Examples include exercise, physical therapy or rehabilitation, relaxation techniques, heat/cold therapy, massage, psychological therapy, cognitive behavioral therapy, weight loss, or biofeedback.

    Not Covered

    Extended-duration immediate-release opioid therapy for acute or post-operative pain is not covered.

    Policy Summary
    PayerRegence
    PolicyImmediate-release (IR) Opioid Medication Products for Pain
    Policy CodePolicy dru516
    Change TypeNo material change
    Effective DateApril 1, 2026
    Last ReviewJan 22, 2026
    Next Review DateJanuary 1, 2027
    Key ActionFor non-cancer pain, document insufficient response to both non-opioid and non-pharmacological therapy unless medically contraindicated.
    SourceLink
    On This Page
    Coverage CriteriaCoverage and Review ParametersProvider Requirements and Action ItemsPolicy BackgroundKey DefinitionsConservative Treatment RequirementsNot Covered
  1. C. Sickle cell disease: The patient has a diagnosis of sickle cell disease.

  2. D. Non-cancer pain

    • 1. Maximized conservative therapy

      • Non-opioid therapy is used and documented, such as acetaminophen, NSAIDs, antiepileptics, or antidepressants.
      • Non-pharmacological therapy is used and documented, such as exercise, physical therapy or rehabilitation, relaxation techniques, heat/cold therapy, massage, psychological therapy, cognitive behavioral therapy, weight loss, or biofeedback.
    • 2. Patient-specific treatment plan: Clinical documentation, such as chart notes, addresses the patient-specific goals of opioid therapy, including an individualized plan to reach the lowest effective opioid dose in the shortest feasible time.Reassess at least every 6 months
    3. Provide current clinical documentation confirming that the comprehensive pain-management plan has been assessed and updated and that the patient is making progress toward the stated goals of opioid therapy.
    Initial review at 6 months; continued review at least every 6 months

    Document the ongoing source of pain and continued medical necessity.

  3. Concurrent medication-assisted treatment, when applicable: When an immediate-release opioid is used concurrently with buprenorphine or buprenorphine/naloxone for opioid-dependence treatment, the prescriber provides documentation supporting the concurrent use.
    4. The grace fill helps prevent opioid withdrawal during the pre-authorization submission and review process
    Treatment-plan reassessment
    Reassessment intervalAt least every 6 months
    Plan reviewThe comprehensive treatment plan is addressed at patient evaluations
    Plan focusThe plan includes an individualized approach to reach the lowest effective opioid dose in the shortest feasible time
    Cancer-related pain authorization review
    Authorization reviewReview at 12 months
    Qualifying painOngoing pain due to an active malignancy supports continued authorization
    Alternative pathwayFor patients without clear documentation of pain due to an active malignancy, the non-cancer pain initial criteria must be met
    Sickle cell disease authorization review
    Authorization reviewReview every 12 months
    Qualifying conditionAcute episodic pain associated with sickle cell disease
    Review timingAuthorization may be reviewed every 12 months
    Non-cancer pain continued authorization review
    Continued authorization reviewAt least every 6 months
    Current documentationDocumentation must confirm that the comprehensive pain-management treatment plan has been assessed and updated
    Treatment responseThe patient must be making progress toward the stated goals of opioid therapy
    Opioid-naive dose
    Recommended maximum50 morphine milligram equivalents per day for opioid-naive patients
    Higher-dose concernDoses above 50 MME per day often do not provide additional benefit in pain or function
    Associated risksHigher doses are associated with increased risks of misuse, overdose, and death
  4. Non-cancer pain when required non-opioid and non-pharmacological therapies are maximized and documented as insufficient or medically contraindicated, and a patient-specific opioid treatment plan is documented.
    5. Note

    One-Time Short-Term Authorization

    If the member is new to the plan but already established on the requested medication, grant a one-time, one-month authorization even when the usual coverage criteria are not yet met.

    • Notify the member and prescriber of the short-term authorization and the criteria required for continuation.
    • No further short-term authorizations are granted.
    • Do not count the short-term authorization toward authorization timeframes if the member later meets all coverage criteria.
    Step Therapy

    Required Conservative Treatment

    For non-cancer pain, document that conservative treatment has been maximized and was insufficient for pain control, unless step therapy is medically contraindicated.

    • Document maximized non-opioid therapy, such as acetaminophen, NSAIDs, antiepileptics, or antidepressants.
    • Document maximized non-pharmacological therapy, such as exercise, physical therapy or rehabilitation, relaxation techniques, heat or cold therapy, massage, psychological therapy, cognitive behavioral therapy, weight loss, or biofeedback.
    • If these therapies were not used, document the medical contraindication.
    • Failure to document insufficient response or a valid contraindication creates denial risk.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Extended Therapy for Acute or Post-Operative Pain

    Extended-duration IR opioid use for acute pain, including post-operative pain, is considered not medically necessary and is not coverable.

    • For acute severe post-operative pain in opioid-naïve patients, use the lowest effective IR opioid dose for no longer than the expected duration of severe pain.
    • If severe pain is prolonged, evaluate the patient for chronic pain and associated extended-duration opioid therapy.
    • For opioid-tolerant surgical patients, baseline chronic-pain opioids may continue under the outpatient regimen, with short-term IR opioids for additional acute pain.

    Unsupported block type: denial_risk

    Unsupported block type: documentation

    Unsupported block type: billing_rule

    Separate review requirementsContinued authorization is reviewed separately for cancer-related pain, sickle cell disease, and non-cancer pain
    Opioid tolerant/experienced
    Minimum exposure durationReceiving the opioid for one week or longer
    Morphine-equivalent thresholdAt least 60 mg of oral morphine per day
    Other qualifying exposures25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid
    MAT
    MAT meaningMedication-assisted treatment for opioid addiction or opioid use disorder
    BuprenorphineBuprenorphine is used as medication-assisted treatment, including office-based opioid-dependence treatment
    Combination treatmentMAT includes buprenorphine/naloxone treatment
    PDMP
    PDMP meaningA state prescription monitoring program database
    UseUsed to assess use and overuse of opioids and other controlled substances, including sedatives
    Provider actionPatients must be assessed through the applicable state PDMP for overuse of opioids and other controlled substances